• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Overview Of Ich New E9
 

Overview Of Ich New E9

on

  • 7,176 views

An overview of the ICH E9 guidance. Easy to follow, and I can provide a live presentation of this to your team! Great for those who are not familiar with statistics.

An overview of the ICH E9 guidance. Easy to follow, and I can provide a live presentation of this to your team! Great for those who are not familiar with statistics.

Statistics

Views

Total Views
7,176
Views on SlideShare
7,154
Embed Views
22

Actions

Likes
2
Downloads
0
Comments
0

4 Embeds 22

http://www.linkedin.com 15
http://www.lmodules.com 5
http://www.docshut.com 1
http://www.slashdocs.com 1

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Overview Of Ich New E9 Overview Of Ich New E9 Presentation Transcript

    • Overview of ICH E9: Statistical Principles for Clinical Trials Presented by Jeff Davidson
    • ICH E9 cover page
        • INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
      • ICH HARMONISED TRIPARTITE GUIDELINE
      • STATISTICAL PRINCIPLES FOR CLINICAL TRIALS
      • E9
      • Current Step 4 version dated 5 February 1998
      • This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA.
      • The great tragedy of science -
      • the slaying of a beautiful hypothesis
      • by an ugly fact. 
      • - Aldous Huxley
      • The most important science in the whole world:
      • for upon it depends the practical application of every other science
      • and of every art: the one science essential to all political and social
      • administration, all education, all organization based on
      • experience, for it only gives results of our experience. 
      • - Florence Nightingale
      • Focus on statistical principles
        • Gives direction to researchers in design, conduct, analysis, and evaluation of trials
        • Does not address use of specific statistical tests
        • Emphasis on later phase, confirmatory trials
      • Target audience: individuals from a broad range of scientific disciplines
        • Statisticians, clinicians, pharmacologists, epidemiologists
      Scope and Direction
      • Trial Statistician:
        • Responsible for all the statistical work associated with the trial
        • Ensures statistical principles are appropriately applied
        • Has the proper training and experience to implement the principles in this guidance
      Unjustified statistics are like smiling cats - not to be trusted. Scope and Direction
      • Minimizing bias
        • Systematic tendency of any factors associated with design, conduct, analysis and interpretation
        • To lead to an estimate of treatment effect
        • Different from the true value
      • Maximizing precision
        • Obtaining small standard errors and narrow confidence intervals
      • Evaluating robustness
        • Sensitivity of overall conclusions to various limitations of the data, assumptions, analysis procedures used
      Scope and Direction
      • Controlling the type I error
        • Ensuring that the chance of declaring a treatment efficacious when it in fact does not work is low (e.g., α ≤ 0.05)
      • “ Multiplicity” refers to having more than one opportunity to detect a difference between drugs (e.g., interim analyses, multiple endpoints of interest)
      Scope and Direction
      • Principal features of statistical analysis should be clearly specified in the protocol
      • Protocol (and amendments) should be approved by a trained statistician
      • A detailed Analysis Plan should be written before data analysis begins
      Protocol and Analysis Plan
    • Types of Trials
      • Exploratory Trial
      Confirmatory Trial
    • Exploratory Trial
      • Clear and precise objectives, however, tests of hypothesis may be data dependent
      • Such trials cannot be the basis of the formal proof of efficacy
    • Confirmatory Trial
      • An adequately controlled trial in which the hypotheses are stated in advance and evaluated
      • Key hypothesis of interest
        • Follows directly from the trial’s primary objective
        • Is always pre-defined
        • Is the hypothesis that is subsequently tested when the trial is complete
      • Adherence to protocols and SOPs is particularly important
    • Population
      • Earlier phases may focus on a very narrow subgroup
      • Confirmatory trials should more closely mirror target population of the therapy under study
        • Issues of Generalizability
      • Clear Inclusion/Exclusion criteria
    • Outcome Variables
      • Primary variable(s)
        • Directly related to the primary objective
        • Preferable to specify only one reliable and validated variable
        • Used in earlier studies or in published literature
        • Used when estimating the sample size
      • Secondary variables
        • Either supportive measurements related to the primary objective, or measurements of effects related to the secondary objectives
    • Avoiding Bias by Design: Blinding
      • Blinding limits the occurrence of conscious and unconscious bias arising from the influence one’s knowledge of treatment may have on
        • Recruitment and allocation of subjects
        • Their subsequent care
        • Attitudes of subjects to the treatments
        • Assessment of endpoints
        • Handling of withdrawals
        • Exclusion of data from analysis
        • Choice of analysis methods
    • Avoiding Bias by Design: Randomization
      • Introduces a deliberate element of chance into the assignment of treatments
      • Provides a sound statistical basis for the comparison of treatment groups
      • Tends to produce treatment groups with distributions of prognostic factors (measured and unmeasured) are similar
      • Parallel group: random assignment to A vs B
      • Randomization
      Design Configuration Population A B
      • Crossover:
      • random assignment to AB or BA
      • subject serves as own control
      • Randomization Washout period
      Design Configuration Population A B B A
      • Factorial Designs:
      Design Configuration Population A (A1, A2) B (B1,B2) A1, B1 A1, B2 A2, B1 A2, B2
    • Other Study Designs
      • Cohort Studies
      • Case-Control Studies
      • Descriptive Studies (e.g., surveys)
      • Registries
      • Adaptive
      • Etc., etc…
    • Type of Comparison
      • Trials to show “superiority”
        • New treatment vs. placebo, or new treatment vs. active control
        • Test (and hopefully reject) the null hypothesis that there is no difference in outcomes between groups
        • vs. the alternative hypothesis that there is a difference between the groups
        • One-sided or two-sided
    • Type of Comparison
      • Trials to show “ equivalence ”
        • New treatment vs. active control
        • Test (and hopefully reject) the null hypothesis that the new treatment performs differently than the active control by at least some small amount
        • vs. the alternative hypothesis that the difference between the groups is no greater than this small amount
          • An amount that is sufficiently small that the treatments are considered equivalent for all practical purposes if the difference between the treatments is smaller than this amount (equivalence margin)
    • Type of Comparison
      • Trials to show “noninferiority”
        • New treatment vs. active control
        • Test (and hopefully reject) the null hypothesis that the active control performs better than the new treatment by at least some small amount
        • vs. the alternative hypothesis that the new treatment does not perform worse than the active control by more than this small amount
    •  
    • Type of comparison
      • Trials to show “equivalence”
        • e.g., test null hypothesis that % cured with active
        • Control is ≥ 5% more than the % cured with the new treatment and vice versa
      • Trials to show “noninferiority”
        • e.g., test null hypothesis that % cured with active
        • Control is ≥ 5% than the % cured with the new treatment
    • Sample Size
      • Determine based on:
      • A primary endpoint
      • The null hypothesis
      • The test statistic (e.g., t-test, chi-square test, logrank test)
      • The treatment difference to be detected (the “alternative hypothesis”)
      • Significant level (Type I error)
      • Desired power (Type II error)
      • Variability assumptions
      • The plan for handling treatment withdrawals and protocol violations
    • Data Monitoring
      • Oversight of Trial Quality
      • Monitoring of Treatment Effects
    • Oversight of Trial Quality
      • Checks performed in a blinded manner:
        • Whether the protocol is being followed
        • The acceptability of data being accrued
        • The success of planned accrual targets
        • The appropriateness of the design assumptions
        • Success in keeping patients in the trials
      • Has no impact on Type I error
    • Monitoring Treatment Effects: Interim Analysis
      • Usually for serious outcomes
      • Requires unblinded access to treatment group summary data
      • Should only be done if included in the protocol
      • Goal, stop the trial early if:
        • Superiority of the new treatment is clear
        • Future demonstration of a treatment effect is unlikely
        • Unacceptable adverse effects are apparent
    • Monitoring Treatment Effects: Interim Analysis
      • May require a DMC, which should approve interim plans
      Independent Statistical Team Study Team IRB Sponsor DMC
    • Monitoring Treatment Effects: Interim Analysis
      • Repeated testing of outcome data increases the chance of a
      • Type I error
      • Test for difference in proportions failing in two groups without adjustment for multiple testing
      • Decision Rule : Reject null if |Z| ≥1.96 Overall Type I Error Rate
      • Single test at end of study -----> 0.05
      • Two tests, equally spaced -----> 0.08
      • Five tests, equally spaced -----> 0.14
      • -(Friedman, Furberg and DeMets, 1996)
    • Data Analysis
      • Include main features of analysis in protocol
      • For confirmatory trial, include statistical methods to be used for the primary variable(s)
      • For exploratory trials, include general principles and directions
      • Additional ‘statistical analysis plan’
        • Detailed procedures for primary and secondary variables
        • Do blind review of data, record date of breaking blind
    • Analysis Sets
      • Disposition of participants enrolled, summary of protocol violations
      • Degree of compliance and missing data lead to different Analysis Sets:
        • Full Analysis Set
        • Per Protocol Set
        • Rationale:
          • Minimize bias (Analysis Sets defined a priori)
          • Demonstrate lack of sensitivity
    • Full Analysis Set
      • ‘ Full analysis set’ = the analysis set which is as complete as possible and as close as possible to the intention-to-treat ideal of including all randomized subjects, it may exclude, for example:
        • Participants who failed to meet a major entry criteria
        • Participants who lack any data post randomization
    • Full Analysis Set
      • If specified in the plan, subjects who fail to meet an entry criterion may be excluded without the possibility of introducing bias under the following circumstances:
        • The entry criterion was measured prior to randomization
        • The detection of the relevant eligibility violations can be made completely objectively
        • All subjects receive equal scrutiny for eligibility violations
        • All detected violations of the particular entry criterion are excluded
    • Per Protocol Set
      • ‘ Per protocol set’ = subset of the participants in the full analysis set who are more compliant with the protocol
        • Complete a certain pre-specified minimal exposure to the treatment regimen
        • Have some minimum number of measurements of the primary variable(s)
        • Have no major protocol violations
      • May give overly optimistic results in superiority trials
      • May be the more conservative analysis set for equivalence or non-inferiority trials
    • Estimation and Confidence Intervals
      • Not just p-values, include confidence intervals for estimated treatment effects
      • Prespecify any covariates to be controlled for in primary or secondary analysis
        • To improve precision
        • To adjust for potential imbalances
        • To account for stratified designs
        • Never adjust for post-randomization variables
      • Prespecify interactions and subgroups of interest if treatment effect is likely to vary by baseline factors (e.g., gender)
    • Evaluation of Safety
      • Choice of variables: Laboratory tests, vital signs, adverse events
      • Safety Analysis Set: Usually those who received at least one dose of the investigational drug
      • Statistical Analysis
    • Example of an unacceptable adverse event
    • Evaluation of Safety is critical to the success of a new drug
    • Reporting
      • Document deviations from analysis plan, when and why they occurred
      • Account for all subjects who entered the study
      • Describe all reasons for exclusion from analysis dataset and all protocol violations
      • Summarize measurements of all important variables
      • Consider the effect of loss of subjects, violations and missing data on analysis results
      • Describe participants lost, withdrawn, etc.
      • Thank you!
      • Questions?